Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.74 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14129854 | 0.85 | CYP2D6 (1.00) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL2608837 | 0.84 | CYP2D6 (0.66) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL9471631 | 0.82 | CYP2D6 (0.77) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL8488413 | 0.81 | CYP2D6 (0.75) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL9451271 | 0.81 | CYP2D6 (0.75) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL8795724 | 0.81 | CYP2D6 (0.75) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL13527033 | 0.80 | CYP2D6 (0.74) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL14129968 | 0.80 | CYP2D6 (1.00) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL8483819 | 0.79 | CYP2D6 (0.73) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL8794635 | 0.79 | CYP2D6 (0.73) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | CYP2D6 285/4885CYP2C9 346/4885CYP3A4 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.